[Long term experience with Stalevo in Szeged, Hungary]
Related Experiment Video
Updated: Jun 21, 2026

Evaluation of the Storage Stability of Extracellular Vesicles
Published on: May 22, 2019
Péter Klivényi1, László Vécsei
1Szegedi Tudományegyetem, Neurológiai Klinika, Szeged. klivenyi@nepsy.szote.u-szeged.hu
Abstract:
The triple combination of levodopa, DDCI and entacapone (Stalevo) is used to treat motor complication in patients with Parkinson's disease. In this study we summarized the clinical data of our patients treated with Stalevo for the longest period. We can concluded, that after switching to Stalevo due to wearing off, the average levodopa doses were lower then before and the motor complications were milder. After 3 years of Stalevo therapy the levodopa doses were increased but still did not reach the average doses before introducing Stalevo. After switching the patients' general well-being was improved as indicated by the visual analogue scale. In summary, the Stalevo treatment is safe and effective for long run and improves the patients' quality of life.
Related Concept Videos
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Drug Product Stability
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Bioequivalence studies: Biowaivers
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
